Clinical trials: Functional Impairment
Functional Impairment, Cognitive Impairment
Optimizing Function and Independence Through iHI-FIVES
Optimizing Function and Independence Through iHI-FIVES aims to implement the iHI-FIVES caregiver skills training program at 8 VAMC sites in a stepped- wedge design and evaluate caregiver and patient outcomes before and after the…
- Trial name
- NCT03474380
- Testing
- iHI-FIVES
- Where
- United States
- Volunteers
- 1,406 people
- Sponsor
- VA Office of Research and Development
COVID-19 Pneumonia, Impaired Respiratory Function
Study of Efficacy and Safety of MAS825 in Patients With COVID-19
This clinical study was designed to assess the efficacy and safety of MAS825 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia…
- Trial name
- MAS-COVID (NCT04382651)
- Testing
- MAS825, Standard of Care (SoC)
- Where
- 21 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Cognitive Impairment, Hypertension
The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial
The purpose of this study is to examine the effects of blood pressure medications on cognition and blood flow in hypertensive elderly patients with cognitive impairment.
- Conditions
- Cognitive Impairment, Hypertension, Aging
- Trial name
- AVEC (NCT00605072)
- Testing
- candesartan, lisinopril, hydrochlorothiazide
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Southern California
Renal Impairment, Healthy Volunteers
A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys
It is hoped that mobocertinib will eventually help people with cancer with severely reduced kidney function. The main aim of this study is to learn about the levels of mobocertinib in the blood and urine of participants with…
- Trial name
- NCT04056455
- Testing
- Mobocertinib
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Renal Impairment
A Renal Impairment Study for PF-04965842
This study is a phase 1 non-randomized, open-label, single-dose, parallel-group study of PF 04965842 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with moderate renal…
- Trial name
- NCT03660241
- Testing
- PF-04965842
- Where
- 4 sites in United States, Belgium
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatic Impairment
Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function
This was a multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 in participants with chronic hepatic impairment relative to matched participants with normal hepatic…
- Trial name
- NCT06736223
- Testing
- ITF2357
- Where
- 3 sites in Bulgaria, France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Executive Dysfunction, Depression
iTBS Study for Depression (Randomized)
Executive function deficits are common in late life depression (LLD) and are associated with resistance to antidepressants, poor quality of life, considerable disability and increased suicidal risk.
- Trial name
- NCT03745768
- Testing
- Intermittent Theta Burst Stimulation
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Cardiac Failure, Myocardial Failure
An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic
The purpose of this study is to investigate continuous 8-hour introductions of BMS-986231 in participants with heart failure and weakened heart function given a standard dose of diuretic.
- Conditions
- Cardiac Failure, Myocardial Failure, Congestive Heart Failure, Heart Decompensation
- Trial name
- NCT03730961
- Testing
- BMS-986231, Furosemide
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Persistent Depressive Disorder
Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning
The investigators aimed to assess the ability of a modified version of Behavioral Activation for occupational and social improvement to produce change in: 1. social adjustment, 2. work functioning, 3. avoidance behavior and 4.
- Trial name
- NCT01783080
- Testing
- Behavioral Activation for return to work
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
Mild Cognitive Impairment
A Scalable Model for Promoting Functioning and Well-Being Among Older Adults With Mild Cognitive Impairment Via Meaningful Social Interactions: Project SPEAK!
The goal of this study is to refine and test a strategy for engaging older adults with symptoms of SCD/MCI (subjective cognitive decline/mild cognitive impairment) as volunteers to help English language learners (ELLs) who live…
- Trial name
- NCT04717479
- Testing
- Intervention (videoconferencing)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Solid Tumours
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate hepatic impairment compared to patients with normal hepatic function; Part B will allow…
- Trial name
- NCT01894243
- Testing
- Olaparib tablet dosing
- Where
- 12 sites in Czechia, France and 3 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in…
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Trial name
- SCORED (NCT03315143)
- Testing
- Sotagliflozin
- Where
- 754 sites in United States, Argentina and 43 more
- Volunteers
- 10,584 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetic Kidney Disease
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.
- Trial name
- NCT02509624
- Testing
- Selonsertib
- Where
- 5 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Renal Impairment
Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function
This is a Phase 1 study to assess the pharmacokinetics (PK) of IK-1001 (sodium sulfide) in healthy volunteers as well as in subjects with varying degrees of impaired renal function.
- Trial name
- NCT00879645
- Testing
- Sodium Sulfide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Respiratory Insufficiency, Depression
Behavioral Activation-Rehabilitation to Improve Depressive Symptoms & Physical Function After Acute Respiratory Failure
More and more people are surviving after receiving life support for respiratory failure in the intensive care unit, but these patients often experience problems with depression and physical functioning that lead to reduced…
- Conditions
- Respiratory Insufficiency, Depression, Rehabilitation, Critical Care
- Trial name
- BEHAB (NCT03431493)
- Testing
- Behavioral Activation - Rehabilitation
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Johns Hopkins University
Depression
Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression
This study will evaluate the safety and effectiveness of methylphenidate in improving cognition and function in older adults with depression.
- Trial name
- NCT00602290
- Testing
- Citalopram, Methylphenidate (MPH)
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- University of California, Los Angeles
Anesthesia
Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)
The current trial was designed to investigate the effects of 4.0 mg.kg-1 of sugammadex on efficacy, safety and pharmacokinetics in subjects with severe renal impairment in comparison to subjects with normal renal function.
- Trial name
- NCT00702715
- Testing
- sugammadex
- Volunteers
- 69 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain Fog
Transcranial Direct Current Stimulation (tDCS)
Cognitive impairment refers to when an individual struggles to learn, concentrate, remember, or make decisions. This can be due to underlying neurological diseases (i.e.
- Trial name
- tDCS (NCT05524233)
- Testing
- Active Transcranial Direct Stimulation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine
Mild Cognitive Impairment (MCI)
Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)
This research is being done to find out if daily use of the drug levetiracetam can improve memory function in individuals with memory problems like those associated with Mild Cognitive Impairment (MCI) and Alzheimer's disease…
- Trial name
- NCT01044758
- Testing
- Levetiracetam 62.5mg, Levetiracetam 125mg, Levetiracetam 250mg
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Long QT Syndrome
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral eleclazine and its metabolite, GS-623134, in participants with normal and impaired hepatic function.
- Trial name
- NCT02412098
- Testing
- Eleclazine
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences